Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.

June 17, 2026 updated by: Institute of Liver and Biliary Sciences, India

Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients : A Placebo Controlled Randomised Trial

This placebo controlled randomized control study aims to analyze the effect of UDCA supplementation on liver regeneration in Living Donor Liver Transplant (LDLT) recipients. All eligible LDLT recipients during the study period will be included in the study and randomized into two groups. One group will receive Tab UDCA starting atleast 10 days pre-operatively and continued till post-operative day 10 and the other group will receive placebo. UDCA will be given at a dose of 15mg/kg per day in two divided doses. Recipients who are not willing to participate in the study, have hypersensitivity to UDCA will be excluded from the study. Pediatrics recipients and acute liver failure recipients will also be excluded.

Pre- operative, intra-operative and post-operative data will be collected from medical records, electronic hospital information system (HIS) and radiological images collected from the hospital Picture archiving and communication system (PACS). The enrolled subjects will be followed up till for a period of 14 days after the transplant till NCCT Abdomen is done and regenerated liver volumes are analyzed. The anatomic(volumetric), functional(liver function tests) and regenerative biomarkers (HGF, TNF-Alpha, IL6, TGF-Beta1) will be compared between the two groups. Evaluation of incidence of Early Allograft Dysfunction (EAD) as per Modified Olthoff criteria1 will be done between the two groups. FXR receptor concentration (hepatocytes) and TGR-5 receptor concentration (cholangiocytes) will be seen in the explant liver along with evaluation of monocyte number and function and mitochondrial and nuclear DNA.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

130

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • India
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110070

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

All Adult Living Donor Liver Transplant (LDLT) Recipients in ILBS from ethical board clearance to December 2027 in the Department of HPB Surgery and Liver Transplantation, Institute of Liver and Biliary Sciences

Exclusion Criteria:

  • Unwillingness to participate
  • Hypersensitivity to UDCA
  • Patients receiving UDCA pre-operatively within 1 month of liver transplant (PBC and patients of overlap syndrome)
  • Right posterior and left laterals grafts
  • Emergency Liver Transplant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ursodeoxycholic acid+standard medical treatment
Other: Standard Medical Treatment
Standard Medical Treatment
Drug: Ursodeoxycholic acid
Tab Ursodeoxycholic acid 15mg/kg in two divided doses
Active Comparator: Placebo+standard medical treatment
Other: Standard Medical Treatment
Standard Medical Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Regenerated liver volume
Time Frame: Post-Operative Day 14
Post-Operative Day 14
Regeneration Liver Indices • Percentage restoration of SLV (Standard liver volume) • Regeneration index (%) : (Regenerated liver volume-GW/GW)x100 • Kinetic growth rate (volume in CC/Day)
Time Frame: Post-Operative Day 14

Regeneration Liver Indices is defined by-

  • Percentage restoration of SLV (Standard liver volume)
  • Regeneration index (percentages) : (Regenerated liver volume-GW/GW)x100
  • Kinetic growth rate (volume in CC/Day)
Post-Operative Day 14

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Liver Function test
Time Frame: Post-Operative Day 1 to Day 7, Day 10 and Day 14
Post-Operative Day 1 to Day 7, Day 10 and Day 14
Change in Coagulation parameter
Time Frame: Post-Operative Day 1 to Day 7, Day 10 and Day 14
Post-Operative Day 1 to Day 7, Day 10 and Day 14
Change in Serum levels of biomarkers.
Time Frame: Post-Operative Day 0, 2, 5 and 7
Post-Operative Day 0, 2, 5 and 7
Daily ascitic fluid output in drain/24hr
Time Frame: Daily till Post-Operative Day 14
Daily till Post-Operative Day 14
Total ascitic fluid output till POD-14
Time Frame: Post-Operative Day 14
Post-Operative Day 14
Bile acid receptors expression for UDCA.
Time Frame: Post-Operative Day 1
{FXR receptor concentration (hepatocytes), TGR-5 receptor concentration (cholangiocytes) of the explant liver}
Post-Operative Day 1
Evaluation of monocyte number and function (flowcytometry)
Time Frame: Post-Operative Day 1
Post-Operative Day 1
Mitochondrial and nuclear DNA (markers of Ischemia-reperfusion injury)- flowcytometry
Time Frame: Post-Operative Day 14
Post-Operative Day 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institute of Liver and Biliary Sciences, India

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 18, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

June 6, 2026

First Submitted That Met QC Criteria

June 17, 2026

First Posted (Actual)

June 23, 2026

Study Record Updates

Last Update Posted (Actual)

June 23, 2026

Last Update Submitted That Met QC Criteria

June 17, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IEC/2026/126/MA01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Liver Disease

Clinical Trials on Standard Medical Treatment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe